Partner with us:
We believe great science comes from working together.
Focus on R&D:
Asahi Kasei Pharma Corporation is focused on the discovery and development of new drugs that address unmet medical needs.
Recent News
- October 13, 2020
- Asahi Kasei Pharma to solicit proposals for drug discovery research
- June 2, 2020
- Asahi Kasei Pharma obtains Chinese approval for Flivas™ (naftopidil) dysuria treatment
- March 19, 2020
- Asahi Kasei Pharma concludes license agreement with SBI Biotech for SBI-3150
- January 9, 2020
- Denial of motion for preliminary injunction requesting continuous supply of XIAFLEX® injection
- November 27, 2019
- Announcement of listing on the NHI drug price standard and marketing of Teribone™ 28.2 µg subcutaneous autoinjector
- November 25, 2019
- Asahi Kasei to Acquire Veloxis Pharmaceuticals Inc.
- November 25, 2019
- Asahi Kasei Pharma licenses fasudil to Woolsey Pharmaceuticals
- October 30, 2019
- Asahi Kasei Pharma to solicit proposals for drug discovery research
